英国单中心泛癌种队列中免疫检查点抑制剂治疗后的甲状腺功能障碍:一项回顾性研究
该回顾性研究在1349例基线甲状腺功能正常的免疫检查点抑制剂(ICI)治疗患者中分析甲状腺功能障碍的发生比例、危险因素、甲状腺后遗症及总生存(OS)。34.2%发生甲状腺功能亢进(10.3%为显性),28.2%发生甲状腺功能减退(显性9.3%,继发性0.5%)。显性功能障碍与OS在Cox分析中相关(HR=0.65),但经时依Cox或landmark分析后关联不明确。
要点
- 接受ICI治疗的患者中,34.2%发生甲状腺功能亢进,28.2%发生甲状腺功能减退。
- 显性甲状腺功能亢进中55.4%进展为显性甲状腺功能减退,中位时间1.6个月。
- 显性功能障碍与OS的关联在考虑永生时间偏倚后不明确。
核心结论
- 甲状腺功能障碍影响多达半数接受ICI治疗的患者,考虑永生时间偏倚后其与OS的关联不明确。
研究设计与样本
- 回顾性研究,纳入英国大型癌症中心1349例基线游离T4(fT4)和促甲状腺激素(TSH)正常并接受ICI治疗的患者。
主要发现
- 34.2%发生甲状腺功能亢进(10.3%为显性),联合ICI治疗者中54.9%发生甲状腺功能亢进;28.2%发生甲状腺功能减退(显性9.3%,继发性0.5%)。
- 三分之一的显性甲状腺功能减退病例无 preceding 甲状腺功能亢进;亚临床甲状腺功能障碍中多达半数直接恢复正常。
- 显性甲状腺功能亢进中55.4%进展为显性甲状腺功能减退,中位时间1.6个月。
- 黑色素瘤辅助治疗对比晚期治疗,显性甲状腺功能亢进发生率12.1% vs 7.5%,显性甲状腺功能减退发生率14.5% vs 9.7%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study investigated thyroid dysfunction with immune checkpoint inhibitors (ICIs) in terms of proportions affected, risk factors, thyroid sequelae, and overall survival (OS). METHODS: Among patients with normal baseline free T4 (fT4) and thyroid stimulating hormone (TSH) receiving ICIs at a large cancer centre, proportions of hyperthyroidism/hypothyroidism were determined (any, subclinical [normal fT4, abnormal TSH], overt [abnormal fT4, abnormal TSH], isolated hyperthyroxinaemia/hypothyroxinaemia and secondary) with onset times and subsequent thyroid statuses. Associations of overt dysfunction with OS were estimated using Cox regression and methods robust to immortal time bias (time-dependent Cox regression and 3- and 6-month landmark analyses). Associations of baseline variables with overt hyperthyroidism and hypothyroidism were estimated using Fine and Gray regression. RESULTS: Of 1349 patients, 34.2% developed hyperthyroidism (10.3% overt), including 54.9% receiving combination ICIs, while 28.2% developed hypothyroidism (overt 9.3%, secondary 0.5%). A third of overt hypothyroidism cases occurred without preceding hyperthyroidism. Subclinical thyroid dysfunction returned directly to normal in up to half. Overt hyperthyroidism progressed to overt hypothyroidism in 55.4% (median 1.6 months). Melanoma treatment in the adjuvant vs. advanced setting caused more overt hyperthyroidism (12.1% vs. 7.5%) and overt hypothyroidism (14.5% vs. 9.7%). Baseline eGFR < 60 mL/min/1.73 m2 (HR=1.68, 1.07-2.63) was associated with overt hyperthyroidism and sex (HR=0.60, 0.42-0.87) and TSH (4th vs. 1st quartile HR=1.87, 1.10-3.19) with overt hypothyroidism. Overt dysfunction was associated with OS in the Cox analysis (HR=0.65, 0.50-0.85, median follow-up 22.2 months) but not in the time-dependent Cox (HR=0.79, 0.60-1.03) or landmark analyses (3-month HR=0.74, 0.51-1.07; 6-month HR=0.91, 0.66-1.24). CONCLUSION: Thyroid dysfunction affects up to half of patients receiving ICIs. The association with OS is unclear after considering immortal time bias. The clinical courses include recovery, thyrotoxicosis and de novo overt hypothyroidism. Adjuvant treatment for melanoma, where longer-term harms are of concern, causes more frequent/aggressive dysfunction.
引用
- Kennedy OJ, Ali N, Lee R, et al. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study. Eur J Cancer. 2024. PMID: 38432099. doi:10.1016/j.ejca.2024.113949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。